Initiating Treatment
As soon as a completed enrollment form is sent to Cycle Vita, our dedicated in-house patient support hub, can provide individualized support to eligible* patients.
Initiating Treatment
As soon as a completed enrollment form is sent to Cycle Vita, our dedicated in-house patient support hub, can provide individualized support to eligible* patients.
Switching to TASCENSO ODT
For patients currently taking the same dose (0.25 mg or 0.5 mg) of another fingolimod treatment a first dose observation (FDO) will not be required, providing the patient has not had a lapse in treatment for 14 days or more.1
Our priority is to ensure patients experience a smooth transition from their current disease modifying therapy to TASCENSO ODT.
Starting on TASCENSO ODT
Patients who are currently not on another fingolimod treatment or are increasing their fingolimod dose (from 0.25 mg to 0.5 mg) will need to have baseline assessments (BA) and a FDO to initiate therapy.1
Through the TASCENSO Time Program, eligible patients will have convenient access to in-home FDO and BAs as necessary to initiate their treatment. Our team has extensive experience in the management and delivery of FDO and BAs and is committed to supporting your patients during this process.
References
1. TASCENSO ODT (fingolimod). Prescribing Information. Cycle Pharmaceuticals Ltd.
*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360-8482.